Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 145

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 1B
Chunk 145
---
 as compared to the prior year primarily due to delays in obtaining clearance from the FDA to 

87

proceed with the DOSED study; (ii) a $0.5 million decrease for our preclinical programs; (iii) a $0.6 million decrease for our other research and development programs; and (iv) partially offset by a $0.6 million increase for our OpRegen program.

General and administrative expenses. For the twelve months ended December 31, 2024, the $0.9 million year-over-year increase in general and administrative expenses was primarily attributable to (i) a $0.6 million increase in stock-based compensation; (ii) a $0.4 million increase in personnel costs; and (iii) partially offset by a $0.1 million overall decrease in costs incurred for services provided by third parties.

Other Income and Expenses, Net

The following table shows the amount of other income (expenses), net, during the year ended December 31, 2024 and 2023 (in thousands):

    Year Ended December 31,

    Dollar Increase

    Percent Increase

    Other income (expenses)
     
    2024

    2023

    (Decrease)

    (Decrease)

    Interest income, net
     
    $
    1,715

    $
    1,629

    $
    86

    5%

    Loss on marketable equity securities, net

    (8
    )

    (176
    )

    168

    95%

    Change in fair value of warrant liability

    2,128

    —

    2,128

    100%

    Foreign currency transaction loss, net

    (269
    )

    (544
    )

    275

    51%

    Other income (expense), net

    (670
    )

    542

    (1,212
    )
     
    (224)%

    Total other income (expenses)
     
    $
    2,896

    $
    1,451

    $
    1,445

    100%

Interest income, net. Interest income was greater for the year ended December 31, 2024 as compared to the prior year primarily due to a nominal increase in interest rates and average cash investment balances during 2024 .

Marketable equity securities, net. We expect our net gain or loss on marketable equitable securities to fluct